

# Johan Vekemans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3988115/publications.pdf>

Version: 2024-02-01

32  
papers

2,581  
citations

279798

23  
h-index

414414

32  
g-index

33  
all docs

33  
docs citations

33  
times ranked

2774  
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children. <i>Clinical Infectious Diseases</i> , 2017, 65, S200-S219.	5.8	348
2	Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses. <i>Clinical Infectious Diseases</i> , 2017, 65, S100-S111.	5.8	329
3	Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses. <i>Clinical Infectious Diseases</i> , 2017, 65, S160-S172.	5.8	286
4	Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal Disease Worldwide: Systematic Review. <i>Clinical Infectious Diseases</i> , 2017, 65, S143-S151.	5.8	144
5	Neurodevelopmental Impairment in Children After Group B Streptococcal Disease Worldwide: Systematic Review and Meta-analyses. <i>Clinical Infectious Diseases</i> , 2017, 65, S190-S199.	5.8	138
6	Preterm Birth Associated With Group B Streptococcus Maternal Colonization Worldwide: Systematic Review and Meta-analyses. <i>Clinical Infectious Diseases</i> , 2017, 65, S133-S142.	5.8	138
7	The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics. <i>Clinical Infectious Diseases</i> , 2019, 69, 877-883.	5.8	122
8	Stillbirth With Group B Streptococcus Disease Worldwide: Systematic Review and Meta-analyses. <i>Clinical Infectious Diseases</i> , 2017, 65, S125-S132.	5.8	111
9	Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. <i>JCI Insight</i> , 2017, 2, .	5.0	109
10	Demonstration of the Blood-Stage <i>Plasmodium falciparum</i> Controlled Human Malaria Infection Model to Assess Efficacy of the <i>P. falciparum</i> Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. <i>Journal of Infectious Diseases</i> , 2016, 213, 1743-1751.	4.0	95
11	Maternal Disease With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses. <i>Clinical Infectious Diseases</i> , 2017, 65, S112-S124.	5.8	86
12	Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children: Why, What, and How to Undertake Estimates?. <i>Clinical Infectious Diseases</i> , 2017, 65, S89-S99.	5.8	75
13	WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016. <i>Vaccine</i> , 2019, 37, 7307-7314.	3.8	74
14	Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries. <i>F1000Research</i> , 2016, 5, 2355.	1.6	64
15	Neonatal Encephalopathy With Group B Streptococcal Disease Worldwide: Systematic Review, Investigator Group Datasets, and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2017, 65, S173-S189.	5.8	51
16	Serocorrelates of protection against infant group B streptococcus disease. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e162-e171.	9.1	46
17	Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. <i>Vaccine</i> , 2019, 37, 7394-7395.	3.8	46
18	Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics. <i>Vaccine</i> , 2019, 37, 7391-7393.	3.8	42

#	ARTICLE	IF	CITATIONS
19	Research and development of new tuberculosis vaccines: a review. F1000Research, 2018, 7, 1732.	1.6	38
20	The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. Vaccine, 2019, 37, 3190-3198.	3.8	35
21	WHO preferred product characteristics for new vaccines against tuberculosis. Lancet Infectious Diseases, The, 2018, 18, 828-829.	9.1	31
22	Research and development of new tuberculosis vaccines: a review. F1000Research, 2018, 7, 1732.	1.6	27
23	Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions. Vaccine, 2019, 37, 4877-4885.	3.8	22
24	Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. Frontiers in Immunology, 2021, 12, 694759.	4.8	22
25	Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations. Vaccine, 2020, 38, 135-142.	3.8	20
26	Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance's 2018 Vaccine Investment Strategy: report from an expert survey. F1000Research, 2019, 8, 1685.	1.6	18
27	Meeting report: WHO consultation on malaria vaccine development, Geneva, 15-16 July 2019. Vaccine, 2021, 39, 2907-2916.	3.8	10
28	A new tuberculosis vaccine: breakthrough, challenges, and a call for collaboration. Lancet Infectious Diseases, The, 2019, 19, 123-125.	9.1	8
29	Tuberculosis vaccines: Rising opportunities. PLoS Medicine, 2019, 16, e1002791.	8.4	8
30	The case for assessing the full value of new tuberculosis vaccines. European Respiratory Journal, 2020, 55, 1902414.	6.7	8
31	HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use. Lancet HIV, the, 2020, 7, e141-e148.	4.7	2
32	Group A Streptococcus Vaccines. , 2021, , 275-288.		0